ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1763

Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis

Lucas Benarous1, Benjamin Terrier2, Bertrand Dunogué3, Pascal Cohen4, Xavier Puéchal4, Claire Le Jeunne4, Luc Mouthon4 and Loïc Guillevin for the French Vasculitis Study Group4, 1Cochin Hospital, Paris, France, 2National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, 3Internal Medicine, Hôpital Cochin, Paris, France, 4National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Churg-Strauss syndrome, tobacco use and vasculitis, Wegener's granulomatosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Occupational and non-occupational exposures may play a role in the occurrence of ANCA-associated vasculitides (AAV) and affect their initial clinical-biological phenotype. Among these potential exposures, tobacco use could represent a factor that could influence AAV characteristics at diagnosis. However, these effects could differ according to the type of AAV, since granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) involve different pathophysiological mechanisms.

Methods

AAV patients entered in the FVSG database with available information on previous and current smoking habits were analyzed. The clinical-biological phenotype at diagnosis was compared according to current tobacco use (current smokers) or not (including previous and never smokers).

Results

This analysis concerned 1165 patients (545 men and 620 women; mean age of 52.8±16.1 years). AAV diagnoses were: GPA for 583 (50%), MPA for 256 (22%) and EGPA for 326 (28%). Among them, 973 patients (84%) were never smokers, 116 (10%) were previous smokers and 76 (6%) were current smokers. Among GPA patients, current smokers (n=55), compared to non-current smokers (n=528) respectively, were younger (44.5±13.5 vs. 52.0±16.3, P=0.0001), more frequently men (64 vs. 48%, P=0.016) and had more frequent cutaneous involvement (50 vs. 32%, P=0.025), and tended to have more frequent arthralgias (67 vs. 54%, P=0.11) and less frequent constitutional symptoms (33 vs. 47%, P=0.08) and ear, nose & throat (ENT) involvement (73 vs. 83%, P=0.13). BVAS, PR3-ANCA–positivity and inflammatory parameters were similar for the 2 groups. Among EGPA patients, current smokers (n=15), compared to non-current smokers (n=311) respectively, were also younger (41.1±15.8 vs. 50.3±15.2, P=0.028) and had less frequent constitutional symptoms (29 vs. 62%, P=0.02), arthralgias (7 vs. 35%, P=0.04), renal involvement (0 vs. 26%, P=0.025) and MPO-ANCA–positivity (0 vs 30%, P=0.02). BVAS and inflammatory parameters were comparable for the 2 groups. Finally, analysis of MPA patients was impossible because only 6 (2%) were current smokers. 

Conclusion

These results suggest that tobacco use could differentially affect GPA and EGPA clinical-biological phenotypes, while no conclusion can be drawn for MPA. Moreover, they support the role of environmental exposures in AAV development and its phenotype.   


Disclosure:

L. Benarous,
None;

B. Terrier,
None;

B. Dunogué,
None;

P. Cohen,
None;

X. Puéchal,
None;

C. Le Jeunne,
None;

L. Mouthon,
None;

L. Guillevin for the French Vasculitis Study Group,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tobacco-differentially-affects-the-clinical-biological-phenotype-of-anca-associated-vasculitides-at-diagnosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology